PEPTIDE

PT-141 (Bremelanotide)

Melanocortin-4 receptor agonist; FDA-approved (Vyleesi) for premenopausal HSDD via central melanocortin signaling.

BIOGATE · GREEN | POSTERIOR 65.0% | MW 1025.2 | 42AA

SEQUENCE

Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH

Modifications: cyclic lactam; acetylated N-terminus; Nle[1]

PDA-V1 chain of custody

Outer hash

63985847629856-b465985b6d649859da5f9851fb5e9850686198552160985 38e

Merkle root

b04c8a9eb14c8c31ae4c8778af4c890bb44c90eab54c927db24c8dc4b34c8f57

TEE attestation

02-b3bc7003b3be0304b3bf9605b3c12906b3c2bc07b3c44f08b3c5e209b3c775

Inputs

b3afc-cc7b2afcb34b5afcfedb4afce5aafafc67baeafc4e8b1afc9a1b0af

Living Outcome Oracle

± =63.8 ² =34.3 **P(success) = 65.0%**

95% CI [53.0%, 77.0%]

Seven-rule export gate

7 / 7 rules satisfied · audience: researcher · Full attestation set, raw posteriors, all hashes

- Grade A or B citation present on the core claim
- BioGate verdict is GREEN or AMBER (RED/BLACK refused)
- Jurisdiction permits the audience-appropriate use
- RWE summary attached when claim depends on outcome data
- Prediction-outcome pairs disclosed when posterior cited
- No human-use claim beyond cited indications
- COA registry lookup available for any synthesis claim

Citations

GRADE A

Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder

2019 · Obstet Gynecol

Kingsberg SA et al.

PMID 30923458